Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Within 90 minutes after receiving a single intravenous dose of the drug, all six volunteers had a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypotension. Within 12 to 16 hours after infusion, they became critically ill, with pulmonary infiltrates and lung injury, renal failure, and disseminated intravascular coagulation. Severe and unexpected depletion of lymphocytes and monocytes occurred within 24 hours after infusion. All six patients were transferred to the care of the authors at an intensive care unit at a public hospital, where they received intensive cardiopulmonary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor antagonist antibody. Prolonged cardiovascular shock and acute respiratory distress syndrome developed in two patients, who required intensive organ support for 8 and 16 days. Despite evidence of the multiple cytokine-release syndrome, all six patients survived. Documentation of the clinical course occurring over the 30 days after infusion offers insight into the systemic inflammatory response syndrome in the absence of contaminating pathogens, endotoxin, or underlying disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although the solid phase assay does not replicate in vivo presentation of TGN1412, which is not fully understood, it does induce substantial cytokine release equivalent to that reported in trial volunteers.”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly occurred in all six healthy volunteers during the phase I clinical trial of the CD28 superagonist monoclonal antibody (mAb) TGN1412.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“One of the most striking features of the TGN1412-mediated 'cytokine storm' observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“Concentrations of TNF-a measured by ELISA in culture supernatants collected 24 h after in vitro TGN1412 stimulation were also consistent with the peak concentrations reported in trial volunteers, with the considerable caveat that a comparison is being made between an in vitro system and an in vivo response.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“However, despite similar in vitro expression kinetics for IFN-g following TGN1412 stimulation, the concentrations of IFN-g were far lower than TNF-a responses in vitro, and an order of magnitude lower than concentrations of IFN-g predicted from in vivo responses in trial participants (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“10.1073/pnas.0501997102”
Cited work 10.1073/pnas.0501997102 · retracted 2009-07-09 · notice 10.1073/pnas.0906977106 · this paper published 2006-09-07
Citations
Cites
1 retracted
Gon, Y., Wood, M. R., Kiosses, W. B., Jo, E., Sanna, M. G., Chun, J., & Rosen, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501997102 · Cited by 128
RetractedBone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J. R., Morris, A., & Spragg, R. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.3.7509706 · Cited by 6,746
Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans
Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E., Schmieg, R. E., Hui, J. J., Chang, K. C., Osborne, D. F., Freeman, B. D., Cobb, J. P., Buchman, T. G., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6952 · Cited by 934
Clinical risks for development of the acute respiratory distress syndrome.
Hudson, L. D., Milberg, J. A., Anardi, D., & Maunder, R. J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842182 · Cited by 890
Brivet, F. G., Kleinknecht, D. J., Loirat, P., & Landais, P. J. M. (1996) · Critical Care Medicine · doi:10.1097/00003246-199602000-00003 · Cited by 879
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Cited by
Items 701–800 of 2,162
Leach, M. W., Clarke, D. O., Dudal, S., Han, C., Li, C., Yang, Z., Brennan, F. R., Bailey, W. J., Chen, Y., Deslandes, A., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2009 · Cited by 36
“Shortly after the MRSD guidance was released, the FIH trial of TGN1412 (TeGenero AG, Würzburg, Germany) was conducted in which six HVs experienced severe adverse events (SAEs) following administration of the FIH starting dose.(2) In follow-up investigations, it was determined that the starting dose for this anti-CD28…”
MethodStrategies to overcome resistance to immune checkpoint blockade in lung cancer
Attili, I., Tarantino, P., Passaro, A., Stati, V., Curigliano, G., & de Marinis, F. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.02.035 · Cited by 34
de Jesús, D. G. T., Flores-López, N. S., Chávez, J. A. C., & Hernandez-Martinez, A. R. (2021) · Surfaces and Interfaces · doi:10.1016/j.surfin.2021.101456 · Cited by 38
Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis
Narendran, G., Padmapriyadarsini, C., Swaminathan, S., & Tripathy, S. P. (2016) · AIDS Research and Therapy · doi:10.1186/s12981-016-0118-7 · Cited by 39
Schreiner, J., Thommen, D. S., Herzig, P., Bacac, M., Klein, C., Roller, A., Belousov, A., Levitsky, V., Savic, S., Moersig, W., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1062969 · Cited by 39
“However, the translation of such combinatorial approaches into the clinic requires an in-depth understanding of the effects elicited by potent T-cell stimulation as severe unexpected reactions such as massive cytokine release have been observed in a clinical phase I trial after superagonistic anti-CD28 treatment.(47)…”
BackgroundAptamers: A New Technological Platform in Cancer Immunotherapy
Pastor, F. (2016) · Pharmaceuticals · doi:10.3390/ph9040064 · Cited by 33
Bone marrow-liver-thymus (BLT) immune humanized mice as a model to predict cytokine release syndrome
Yan, H. H., Semple, K. M., Gonzaléz, C. M., & Howard, K. E. (2019) · Translational research · doi:10.1016/j.trsl.2019.04.007 · Cited by 36
Arnone, C. M., Polito, V. A., Mastronuzzi, A., Carai, A., Camassei, F. D., Antonucci, L., Petrilli, L. L., Vinci, M., Ferrari, F., Salviato, E., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001930 · Cited by 33
Wang, H., Liu, H., Li, J., Liu, C., Chen, H., Li, J., Sun, C., Guo, T., Pang, Z., Zhang, B., et al. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.09.012 · Cited by 39
Melanoma Immunotherapy: Historical Precedents, Recent Successes and Future Prospects
Raaijmakers, M. I. G., Rozati, S., Goldinger, S. M., Widmer, D. S., Dummer, R., & Levesque, M. P. (2013) · Immunotherapy · doi:10.2217/imt.12.162 · Cited by 34
Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes
Horn, L. A., Long, T. M., Atkinson, R. S., Clements, V. K., & Ostrand‐Rosenberg, S. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0026 · Cited by 38
“healthy recipients critically ill with a systemic inflammatory response and cytokine release syndrome (“cytokine storm”) (61).”
The Contribution of Liver Sinusoidal Endothelial Cells to Clearance of Therapeutic Antibody
James, B. H., Papakyriacou, P., Gardener, M. J., Gliddon, L., Weston, C. J., & Lalor, P. F. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2021.753833 · Cited by 39
The critical impacts of cytokine storms in respiratory disorders
Tramboo, S. R., Elkhalifa, A. M. E., Khursheed, S. Q., Ali, S. I., Shah, N. N., Taifa, S., Rakhshan, R., Shah, I. H., Mir, M. A., Malik, M., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29769 · Cited by 38
Lefebvre, D. E., Pearce, B., Fine, J. H., Chomyshyn, E., Ross, N., Halappanavar, S. S., Tayabali, A. F., Curran, I. H., & Bondy, G. S. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu010 · Cited by 33
“…signaling through the CD28 costimulatory receptor on activated T cells synergized with the OVAp-specific T cell receptor to enhance proliferation as well as IL-4, IL-10, and IL-13, consistent with previous reports (Blankson and Morse, 1994; Hunig et al., 2010; Suntharalingam et al., 2006).”
ResultCD19-Targeted T Cells for Hematologic Malignancies: Clinical Experience to Date
Davila, M. L., Sauter, C. S., & Brentjens, R. J. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000153 · Cited by 40
“First, widespread activation of T cells can mediate a similar constellation of symptoms as reported by clinical trials using anti-CD28 or blinatumomab antibodies, which both activate T cells enmasse.(25,26) Furthermore, the majority of the neurotoxicities occur in patients with severe CRS.”
Human IgG subclass cross-species reactivity to mouse and cynomolgus monkey Fcγ receptors
Derebe, M. G., Nanjunda, R. K., Gilliland, G. L., Lacy, E. R., & Chiu, M. L. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.02.006 · Cited by 37
Yıldızhan, E., & Kaynar, L. (2018) · Journal of Oncological Sciences · doi:10.1016/j.jons.2018.09.002 · Cited by 37
Cancer immunotherapies repurposed for use in autoimmunity
Boardman, D. A., & Levings, M. K. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0359-6 · Cited by 33
Can preclinical drug development help to predict adverse events in clinical trials?
Chi, L. H., Burrows, A. D., & Anderson, R. L. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.08.010 · Cited by 34
Abdeladhim, M., Karnell, J. L., & Rieder, S. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1033705 · Cited by 40
Opal, S. M., & Patrozou, E. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181921497 · Cited by 37
“The potential hazards of phase I clinical trials have been recently exemplified by the ex- perience with the super-agonistic monoclonal antibodies directed against CD28 (50).”
BackgroundInfluentialT cell vaccinology: Exploring the known unknowns
Burchill, M. A., Tamburini, B. A. J., Pennock, N. D., White, J. T., Kurche, J. S., & Kedl, R. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.096 · Cited by 38
Fibbe, W. E., Dazzi, F., & LeBlanc, K. (2013) · Nature Medicine · doi:10.1038/nm.3222 · Cited by 33
Enhanced CD8 T Cell Responses through GITR-Mediated Costimulation Resolve Chronic Viral Infection
Pascutti, M. F., Geerman, S., Slot, E. M., van Gisbergen, K. P. J. M., Boon, L., Arens, R., van Lier, R. A. W., Wolkers, M. C., & Nolte, M. A. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004675 · Cited by 35
“Secondly, boosting adaptive immunity may lead to a detrimental inflammatory response and could cause life-threatening immunopathology [2].”
Clinically validated approaches to the treatment of autoimmune diseases
Carter, P. H., & Zhao, Q. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903418452 · Cited by 33
“In this instance, six patients suffered from severe cytokine storm subsequent to a single administration of TGN1412 [78] A retrospective analysis of the safety studies and manufacturing process did not reveal any points of severe concern [79].”
BackgroundCongy‐Jolivet, N., Probst, A., Watier, H., & Thibault, G. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.06.013 · Cited by 37
Rigby, M. R., Trexler, A. M., Pearson, T. C., & Larsen, C. P. (2008) · Diabetes · doi:10.2337/db07-1712 · Cited by 33
“In part, this is due to unforeseen side effects in preclinical and clinical testing, including thromboembolic events with some anti-CD154 antibodies and lethal cytokine storm with superagonist anti-CD28 antibodies (18,19).”
BackgroundAnaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice
Murphy, J. T., Burey, A. P., Beebe, A. M., Gu, D., Presta, L. G., Merghoub, T., & Wolchok, J. D. (2014) · Blood · doi:10.1182/blood-2013-12-544742 · Cited by 32
“While antibodies targeting costimulatory pathways have shown unquestionable potential in preclinical models, clinical trials using a CD28 superagonist antibody and preclinical experiments using a 4-1BB agonist antibody have had severe adverse immune-mediated side effects (34, 35).”
MethodNonclinical development of biopharmaceuticals
Baumann, A. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.09.013 · Cited by 36
Sibille, M., Patat, A. A., Caplain, H., & Donazzolo, Y. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03741.x · Cited by 35
Humanized Mice, a New Model To Study the Influence of Drug Treatment on Neonatal Sepsis
Ernst, W., Zimara, N., Hanses, F., Männel, D. N., Seelbach-Göbel, B., & Wege, A. K. (2013) · Infection and Immunity · doi:10.1128/iai.01235-12 · Cited by 32
Mathematical modeling for novel cancer drug discovery and development
Zhang, P., & Brusić, V. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.941351 · Cited by 33
“Another drug, TGN1412 that targets CD28 as a superagonist caused multiple organ failures in clinical trials [61,62].”
BackgroundPharmacology-based toxicity assessment: towards quantitative risk prediction in humans
Sahota, T., Danhof, M., & Pasqua, O. E. D. (2016) · Mutagenesis · doi:10.1093/mutage/gev081 · Cited by 38
Development of bispecific T cell engagers: harnessing quantitative systems pharmacology
Qi, T., Liao, X., & Cao, Y. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.09.009 · Cited by 34
In vivo therapeutic efficacy of intra-renal CD40 silencing in a model of humoral acute rejection
Ripoll, È., Pluvinet, R., Torrás, J., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.39 · Cited by 31
Findlay, L., Eastwood, D., Ball, C., Robinson, C. J., Bird, C., Wadhwa, M., Thorpe, S. J., Thorpe, R., Stebbings, R., & Poole, S. (2011) · Journal of Immunological Methods · doi:10.1016/j.jim.2011.06.022 · Cited by 34
Biologic response modifiers: Indications, implications, and insights
Davis, B. P., & Ballas, Z. K. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.02.013 · Cited by 33
Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy
Thakar, M. S., Kearl, T. J., & Malarkannan, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01529 · Cited by 35
Murgaski, A., Kiss, M., Damme, H. V., Kancheva, D., Vanmeerbeek, I., Keirsse, J., Hadadi, É., Brughmans, J., Arnouk, S. M., Hamouda, A. E. I., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0094 · Cited by 36
The Multifaceted Immunology of Cytokine Storm Syndrome
Lee, P. Y., & Cron, R. Q. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200808 · Cited by 35
Bispecific antibodies revolutionizing breast cancer treatment: a comprehensive overview
Lan, H., Chen, M., Yao, S.-Y., Chen, J., & Jin, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1266450 · Cited by 38
“These fi ndings indicated the imperative for thoroughly understanding and mitigating potential toxicities before advancing such therapies into human trials (112).”
BackgroundRadiotracers Used for the Scintigraphic Detection of Infection and Inflammation
Tsopelas, C. (2015) · The Scientific World JOURNAL · doi:10.1155/2015/676719 · Cited by 34
“Unfortunately a high proportion of radiolabeled-mAbs were also withdrawn from the market, the major reason was compromised patient safety [81, 82], and to a lesser extent product quality such as problems with raw materials in the product formulation.”
BackgroundThe road to recovery: translating PD-1 biology into clinical benefit
Riley, J. L., & June, C. H. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.12.001 · Cited by 32
Uzana, R., Eisenberg, G., Sagi, Y., Frankenburg, S., Merims, S., Amariglio, N., Yefenof, E., Peretz, T., Machlenkin, A., & Lotem, M. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101429 · Cited by 31
Botturi, K., Lacoeuille, Y., Cavailles, A., et al. (2011) · Respiratory Research · doi:10.1186/1465-9921-12-25 · Cited by 31
First-in-human clinical trials with vaccines—what regulators want
Goetz, K., Pfleiderer, M., & Schneider, C. K. (2010) · Nature Biotechnology · doi:10.1038/nbt0910-910 · Cited by 35
Büning, H., Uckert, W., Cichutek, K., Hawkins, R. E., & Abken, H. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.131 · Cited by 36
“Forced CD28 costimulation as it occurs by combined CD28 and 4-1BB costimulation may predestine the recipient for a cytokine storm, as does administration of the superagonistic anti-CD28 antibody (Suntharalingam et al. , 2006).”
Agarwal, S., & June, C. H. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0473 · Cited by 30
“Thus, JAK inhibitors can lessen inflammation caused due to CRS. JAK inhibitors such as tofacitinib and baricitinib are safe and can establish plasma concentration of inhibition, but their efficacy in treating patients with COVID-19 remains to be determined (14).”
BackgroundInfluentialKojima, M., Suzuki, K., Takeshita, M., Ohyagi, M., Iizuka, M., Yamane, H., Koga, K., Kouro, T., Kassai, Y., Yoshihara, T., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04874-3 · Cited by 32
Franzese, O. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312848 · Cited by 32
Clouthier, D., Zhou, A. C., & Watts, T. H. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401002 · Cited by 33
Melanoma vaccines: developments over the past 10 years
Klein, O., Schmidt, C., Knights, A. J., Davis, I. D., Chen, W., & Cebon, J. S. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.74 · Cited by 34
Co-stimulate or Co-inhibit Regulatory T Cells, Which Side to Go?
Liu, W., Almo, S. C., & Zang, X. (2016) · Immunological Investigations · doi:10.1080/08820139.2016.1186690 · Cited by 35
“However, intravenous administration of agonistic anti-CD28 mAbs (working name TGN1412) even at sub-clinical dose induced rapid cytokine storms and lead to catastrophic systemic organ failures in patients of a phase 1 clinical trial (Suntharalingam et al., 2006).”
BackgroundBatalha, S., Cristóvão‐Ferreira, S., & Brito, C. (2021) · Cancers · doi:10.3390/cancers13061305 · Cited by 34
Clinically Suspected and Biopsy-Proven Myocarditis Temporally Associated with SARS-CoV-2 Infection
Caforio, A. L. P., Baritussio, A., Basso, C., & Marcolongo, R. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042220-023859 · Cited by 32
Worel, N., Grabmeier‐Pfistershammer, K., Kratzer, B., Schlager, M., Tanzmann, A., Rottal, A., Körmöczi, U., Porpaczy, E. A., Staber, P. B., Skrabs, C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1004703 · Cited by 34
“While the engagement of CD28 with an agonistic CD28 monoclonal antibody was, in fact “too potent in vivo” and induced a highly problematic cytokine storm in six participants of a fist-in-human phase I clinical trial in a previous study (50), engagement of CD27 by varlilumab (CDX-1127), a novel, agonistic, fully human…”
BackgroundTherapeutic Approaches Using Host Defence Peptides to Tackle Herpes Virus Infections
Jenssen, H. (2009) · Viruses · doi:10.3390/v1030939 · Cited by 38
“Additionally, there are also potential side effects with immune modulating drugs, like an inappropriate dysregulation of the immune system causing either sepsis or a cytokine storm [133].”
BackgroundStamova, S., Koristka, S., Keil, J., Arndt, C., Feldmann, A., Michalk, I., Bartsch, H., Bippes, C. C., Schmitz, M., Cartellieri, M., et al. (2012) · Antibodies · doi:10.3390/antib1020172 · Cited by 34
“however some concerns were raised, due to the systemic T-cell activation and severe cytokine release syndrome induced when six healthy volunteers were injected with monospecific “super-agonistic” CD28 antibody [118].”
BackgroundAnimal models of inflammatory bowel disease: how useful are they really?
Kolios, G. C. (2016) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000287 · Cited by 34
“Meanwhile, we need a better designed preclinical testing, to use a specific choice of models for our studies and more careful interpretation of the preclinical results before the initiation of clinical trials in order to ensure safety, avoid unexpected harmful side-effects [54] and to improve our translation rates.”
MethodZhao, L., Yang, Y., Li, W., Li, T., & Gao, Q. (2018) · Immunotherapy · doi:10.2217/imt-2018-0025 · Cited by 31
Human immunology: a case for the ascent of non‐furry immunology
Khanna, R., & Burrows, S. R. (2011) · Immunology & Cell Biology · doi:10.1038/icb.2010.173 · Cited by 30
Findlay, L., Sharp, G., Fox, B., Ball, C., Robinson, C. J., Bird, C., Stebbings, R., Eastwood, D., Wadhwa, M., Poole, S., et al. (2011) · Cytokine · doi:10.1016/j.cyto.2011.03.019 · Cited by 29
“With the exception of IL-6, cytokine levels measured following TGN1412 immobilisation were usually much higher and more representative of those measured in the blood samples taken from the clinical trial volunteers [1,4,11].”
BackgroundResultPalácios, R., & Shah, S. K. (2019) · Trials · doi:10.1186/s13063-019-3843-0 · Cited by 35
Juskewitch, J. E., Platt, J. L., Knudsen, B. E., Knutson, K. L., Brunn, G. J., & Grande, J. P. (2012) · Scientific Reports · doi:10.1038/srep00918 · Cited by 30
Revisiting the Functional Impact of NK Cells
Poli, A., Michel, T., Patil, N. D., et al. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.01.011 · Cited by 29
Dendritic Cells as Targets for Biomaterial-Based Immunomodulation
Eslami-Kaliji, F., Sarafbidabad, M., Rajadas, J., & Mohammadi, M. R. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.9b01987 · Cited by 29
Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives
Liu, L., & Chen, J. (2022) · Medical Review · doi:10.1515/mr-2022-0033 · Cited by 29
“In 2006, anti-CD28 monoclonal antibody TGN1412 was reported to induced strong cytokine storm in health volunteers [93], and was withdrawn from development.”
BackgroundBispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
Alsajjan, R., & Mason, W. P. (2023) · Current Oncology · doi:10.3390/curroncol30090619 · Cited by 37
“Implementing this for clinical use is problematic, however, as previous studies with the systemically delivered CD28 super-agonist resulted in severe and unacceptable toxicity [134].”
ResultReed, D. M., Paschalaki, K. E., Starke, R. D., Mohamed, N. A., Sharp, G., Fox, B. J., Eastwood, D., Bristow, A., Ball, C., Vessillier, S., et al. (2015) · The FASEB Journal · doi:10.1096/fj.14-268144 · Cited by 32
Role of the Immune System in Hypertensive Target Organ Damage
Kvakan, H., Luft, F. C., & Müller, D. N. (2009) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2010.02.004 · Cited by 30
“ago, particularly safety issues require further research (Suntharalingam et al. 2006).”
BackgroundAhlqvist, E., Hultqvist, M. H., & Holmdahl, R. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2600 · Cited by 33
T-Cell Based Immunotherapy in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
O’Brien, K., Gran, B., & Rostami, A. M. (2009) · Immunotherapy · doi:10.2217/imt.09.61 · Cited by 38
Controversies in HIV cure research
Johnston, R., & Barré‐Sinoussi, F. (2012) · Journal of the International AIDS Society · doi:10.1186/1758-2652-15-16 · Cited by 32
Karhu, S. T., Välimäki, M. J., Jumppanen, M., Kinnunen, S. M., Pohjolainen, L., Leigh, R. S., Auno, S., Földes, G., af Gennäs, G. B., Yli‐Kauhaluoma, J. T., et al. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2257-1 · Cited by 38
Future applications of host direct therapies for infectious disease treatment
Thom, R. E., & D’Elia, R. V. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1436557 · Cited by 44
“Indeed targeting host-speci fi c pathways could have devastating effects on the host as seen in the fi rst phase 1 clinical trial of an agonistic anti-CD28 monoclonal antibody, which led to an incapacitating cytokine storm in the volunteers (4).”
BackgroundLaboratory mice engrafted with natural gut microbiota possess a wildling-like phenotype
Runge, S., von Zedtwitz, S., Maucher, A., Bruno, P., Osbelt, L., Zhao, B., Gernand, A. M., Lesker, T. R., Gräwe, K., Rogg, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60554-2 · Cited by 35
Ito, F., & Chang, A. E. (2013) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2013.06.005 · Cited by 38
Wegner, J., Hackenberg, S., Scholz, C. J., Chuvpilo, S. A., Tyrsin, D., Matskevich, A. A., Grigoleit, G. U., Stevanović, S., & Hünig, T. (2015) · Blood · doi:10.1182/blood-2015-01-622704 · Cited by 30
“Although PBMC cultures fail to respond to thismonoclonal Ab (mAb) in soluble form,(13) its application to healthy volunteers in a phase 1 study in 2006 resulted in a life-threatening cytokine release syndrome.(14) The molecular basis for this effect is the strict dependence of CD28-driven T-cell activation on a preact…”
BackgroundHigh content cellular immune profiling reveals differences between rhesus monkeys and men
Magalhaes, I., Vudattu, N. K., Ahmed, R. K. S., Kühlmann‐Berenzon, S., Ngo, Y., Sizemore, D. R., Wehlin, L., Weichold, F., Andersson, J., Skeiky, Y. A. W., et al. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03284.x · Cited by 31
Immunomodulatory approaches for prevention and treatment of infectious diseases
Nijnik, A. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.06.011 · Cited by 29
Therapeutic Drug Monitoring of Belatacept in Kidney Transplantation
de Graav, G. N., Bergan, S., Baan, C. C., Weimar, W., van Gelder, T., & Hesselink, D. A. (2014) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000179 · Cited by 28
“Currently no FDA-approved CD28-antibodies are registered, mainly because of the severe systemic inflammatory response observed in 6 volunteers after administration of the CD28-superagonist TGN1412.”
BackgroundMonoclonal Antibodies Hypersensitivity
dos Santos, R. B., & Galvão, V. R. (2017) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2017.07.003 · Cited by 30
Vandivort, T. C., Horton, D. B., & Johnson, S. B. (2020) · Journal of Clinical and Translational Science · doi:10.1017/cts.2020.493 · Cited by 34
Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome
Azar, M. M., Shin, J. J., Kang, I., & Landry, M. L. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1830760 · Cited by 35
Lin, Z., Huang, Y., Jiang, H., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4548 · Cited by 28
“In that trial, six healthy volunteers suffered severe adverse events soon after TGN1412 antibody administration, while preclinical safety testing in cynomolgus monkeys had suggested that TGN1412 could be tolerated without toxicity (2,3).”
Therapeutic Protein-Based Vaccines
Ahmad, S., Dahiya, V., Vibhuti, A., Pandey, R. P., Tripathi, M. K., & Yadav, M. K. (2023) · Springer eBooks · doi:10.1007/978-981-19-8249-1_13 · Cited by 33
Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412
Dayan, C. M., & Wraith, D. C. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2007.03559.x · Cited by 28
Liposomal Formulations for Nucleic Acid Delivery
(2007) · Antisense Drug Technology · doi:10.1201/9780849387951-16 · Cited by 28
Modulation of toll-like receptor function has therapeutic potential in autoimmune disease
Clanchy, F. I. L., & Sacre, S. M. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.534080 · Cited by 28
“Therapeutic agents that modulate any aspect of the immune system will need to ensure host defense is not compromised or inadvertently activated [158].”
BackgroundInflammation and Sepsis: Past, Present, and the Future
Shankar, R., Melstrom, K. A., & Gamelli, R. L. (2007) · Journal of Burn Care & Research · doi:10.1097/bcr.0b013e318093df16 · Cited by 30
“Although many of them yielded somewhatpromising results in animal models, they have failed to produce meaningful treatment alternatives in large clinical trials.(21,22) A potential reason for the ineffectiveness of many of the sepsis immunotherapies is”
ResultBeyersdorf, N., Ding, X., Blank, G., Dennehy, K. M., Kerkau, T., & Hünig, T. (2008) · Blood · doi:10.1182/blood-2008-03-146662 · Cited by 32
Cytokine Storm and an Anti-CD28 Monoclonal Antibody
Puellmann, K., Beham, A. W., & Kaminski, W. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmc062750 · Cited by 28
Mechanisms of Peptide Vaccination in Mouse Models
van Hall, T., & van der Burg, S. H. (2012) · Advances in immunology · doi:10.1016/b978-0-12-396548-6.00003-2 · Cited by 31
Early-drug development in the era of immuno-oncology: are we ready to face the challenges?
de Olza, M. O., Oliva, M., Hierro, C., Matos, I. G., Martín-Liberal, J., & Garralda, E. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy225 · Cited by 29
Hong, D. I., & Sloane, D. E. (2019) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2019.04.015 · Cited by 30
Exploiting autoimmunity unleashed by low‐dose immune checkpoint blockade to treat advanced cancer
Bakács, T., Moss, R. W., Kleef, R., Szász, M. A., & Anderson, C. C. (2019) · Scandinavian Journal of Immunology · doi:10.1111/sji.12821 · Cited by 33
Fyhrquist, N., Alenius, H. T., & Lauerma, A. (2007) · Dermatologic Clinics · doi:10.1016/j.det.2007.06.002 · Cited by 35
Wei, H.-J., Wu, A. T. H., Hsu, C.-H., Lin, Y.-P., Cheng, W., Su, C., Chiu, W., Whang‐Peng, J., Douglas, F. L., & Deng, W. (2011) · Molecular Therapy · doi:10.1038/mt.2011.152 · Cited by 30
Membrane‐tethered proteins for basic research, imaging, and therapy
Cheng, T., & Roffler, S. R. (2008) · Medicinal Research Reviews · doi:10.1002/med.20127 · Cited by 29
Cabrera, A. G., Dyamenahalli, U., Gossett, J. M., Prodhan, P., Morrow, W. R., Imamura, M., Jaquiss, R. D. B., & Bhutta, A. T. (2009) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2009.06.016 · Cited by 28
Metadata
- Authors
- Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N.
- Affiliations
- Hammersmith Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 1018-1028
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141989396
- Cited by
- 2,164
- References
- 18
- Citations by year
- 2026: 57 · 2025: 73 · 2024: 95 · 2023: 79 · 2022: 79 · 2021: 120 · 2020: 141 · 2019: 94 · 2018: 102 · 2017: 97 · 2016: 117 · 2015: 122 · 2014: 118 · 2013: 120 · 2012: 114
- FWCI
- 80.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- cytokine release syndrome, TGN1412, anti-CD28 monoclonal antibody, systemic inflammatory response syndrome, inflammatory cytokines, acute respiratory distress syndrome, disseminated intravascular coagulation, renal failure, drug-induced immunotoxicity
- MeSH terms
- Adult, Antibodies, Monoclonal, C-Reactive Protein, Critical Care, Double-Blind Method, Hemodynamics, Humans, Hypotension, Infusions, Intravenous, Leukopenia, Male, Multiple Organ Failure, Thrombocytopenia, Cytokines, CD28 Antigens, Disease Progression, APACHE, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.